Historique
Périodique
Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management
(Les effets toxiques aigus de l'"ecstasy" (MDMA) et de ses composants associés : panorama de la physiopathologie et de la prise en charge clinique.)
Auteur(s) :
HALL, A. P. ;
HENRY, J. A.
Année
2006
Page(s) :
678-685
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
77
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
MDMA-ECSTASY
;
TOXICITE
;
EFFET SECONDAIRE
;
CONVULSION
;
HYPERTHERMIE
;
PHARMACOLOGIE
;
PHARMACOCINETIQUE
;
SEROTONINE
Note générale :
British Journal of Anaesthesia, 2006, 96, (6), 678-685
Résumé :
ENGLISH :
Since the late 1980s 'Ecstasy' (3,4-methylenedioxymethamphetamine, MDMA) has become established as a popular recreational drug in western Europe. The UK National Criminal Intelligence Service estimates that 0.5-2 million tablets are consumed weekly in Britain. It has been reported that 4.5% of young adults (15-34 yr) in the UK have used MDMA in the previous 12 months. Clinically important toxic effects have been reported, including fatalities. While the phenomenon of hyperpyrexia and multi-organ failure is now relatively well known, other serious effects have become apparent more recently. Patients with acute MDMA toxicity may present to doctors working in Anaesthesia, Intensive Care and Emergency Medicine. A broad knowledge of these pathologies and their treatment is necessary for anyone working in an acute medical speciality. An overview of MDMA pharmacology and acute toxicity will be given followed by a plan for clinical management.
Affiliation :
Department of Anaesthesia and Intensive Care Medicine, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester LE1 5WW
Royaume-Uni. United Kingdom.
Royaume-Uni. United Kingdom.
Cote :
A02906